Fortitude Family Office’s Madrigal Pharmaceuticals MDGL Stock Holding History

Fortitude Family Office’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.61K	Buy	3 +1	+50%	+$512	﹤0.01%	1567
2026 Q1	$1.05K	Buy	2 +1	+100%	+$478	﹤0.01%	1504
2025 Q4	$582	Hold	1	–	–	﹤0.01%	1649
2025 Q3	$459	Hold	1	–	–	﹤0.01%	1838
2025 Q2	$303	Hold	1	–	–	﹤0.01%	1923
2025 Q1	$331	Hold	1	–	–	﹤0.01%	1100
2024 Q4	$309	Hold	1	–	–	﹤0.01%	1245
2024 Q3	$212	Hold	1	–	–	﹤0.01%	1187
2024 Q2	$280	Hold	1	–	–	﹤0.01%	931
2024 Q1	$267	Hold	1	–	–	﹤0.01%	946
2023 Q4	$231	Buy	+1	New	+$175	﹤0.01%	988

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fortitude Family Office's MDGL Position: Q2 2026 in Review

Fortitude Family Office increased its Madrigal Pharmaceuticals (MDGL) stake by 50% in Q2 2026, buying an estimated $512 and bringing the position to 3 shares worth $1.61K. The position accounts for ﹤0.01% of the portfolio, ranked #1567.

Fortitude Family Office first reported a position in MDGL in Q4 2023 and has held it in 11 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Fortitude Family Office held 3 shares of Madrigal Pharmaceuticals worth $1.61K as of Q2 2026.
Fortitude Family Office bought 1 Madrigal Pharmaceuticals share in Q2 2026, an estimated $512.
Madrigal Pharmaceuticals made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1567 holding.
Fortitude Family Office first reported a position in Madrigal Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.